U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Digestive System Neuroendocrine Neoplasm

MedGen UID:
1658744
•Concept ID:
C4744861
•
Neoplastic Process
Synonym: Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm

Definition

A neuroendocrine neoplasm that arises from any part of the digestive system and has metastasized to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Digestive System Neuroendocrine Neoplasm

Professional guidelines

PubMed

Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors.
Hallet J, Law C; Commonwealth Neuroendocrine Tumours Research Collaborative (CommNETs) Surgical Section
World J Surg 2021 Jan;45(1):213-218. Epub 2020 Aug 14 doi: 10.1007/s00268-020-05727-4. PMID: 32797281
Management of Small Bowel Neuroendocrine Tumors.
Scott AT, Howe JR
J Oncol Pract 2018 Aug;14(8):471-482. doi: 10.1200/JOP.18.00135. PMID: 30096273Free PMC Article
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A
J Clin Oncol 2012 Jul 20;30(21):2691-7. Epub 2012 May 21 doi: 10.1200/JCO.2012.41.6750. PMID: 22614989

Recent clinical studies

Etiology

Mixed neuroendocrine-nonneuroendocrine neoplasms of the gastrointestinal system: An update.
Elpek GO
World J Gastroenterol 2022 Feb 28;28(8):794-810. doi: 10.3748/wjg.v28.i8.794. PMID: 35317101Free PMC Article
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review.
Malla S, Kumar P, Madhusudhan KS
Abdom Radiol (NY) 2021 Mar;46(3):919-935. Epub 2020 Sep 22 doi: 10.1007/s00261-020-02773-3. PMID: 32960304
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F
Ann Oncol 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108. PMID: 28368458
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A
J Clin Oncol 2012 Jul 20;30(21):2691-7. Epub 2012 May 21 doi: 10.1200/JCO.2012.41.6750. PMID: 22614989

Diagnosis

Metastasis to the rectum: A systematic review of the literature.
Janjic O, Labgaa I, Hübner M, Demartines N, Joliat GR
Eur J Surg Oncol 2022 Apr;48(4):822-833. Epub 2021 Oct 10 doi: 10.1016/j.ejso.2021.10.004. PMID: 34656391
Cancers Metastatic to the Liver.
Rashidian N, Alseidi A, Kirks RC
Surg Clin North Am 2020 Jun;100(3):551-563. Epub 2020 Apr 3 doi: 10.1016/j.suc.2020.02.005. PMID: 32402300
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.
Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants
Neuroendocrinology 2019;108(1):18-25. Epub 2018 Aug 28 doi: 10.1159/000493319. PMID: 30153686
Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P
Neuroendocrinology 2017;105(4):412-425. Epub 2017 Aug 12 doi: 10.1159/000475527. PMID: 28803232
Neuroendocrine Tumors.
Basuroy R, Srirajaskanthan R, Ramage JK
Gastroenterol Clin North Am 2016 Sep;45(3):487-507. doi: 10.1016/j.gtc.2016.04.007. PMID: 27546845

Therapy

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B
Science 2021 Feb 5;371(6529):602-609. Epub 2020 Dec 10 doi: 10.1126/science.abb5920. PMID: 33303685
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F
Ann Oncol 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108. PMID: 28368458
Neuroendocrine Tumors.
Basuroy R, Srirajaskanthan R, Ramage JK
Gastroenterol Clin North Am 2016 Sep;45(3):487-507. doi: 10.1016/j.gtc.2016.04.007. PMID: 27546845
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A
J Clin Oncol 2012 Jul 20;30(21):2691-7. Epub 2012 May 21 doi: 10.1200/JCO.2012.41.6750. PMID: 22614989

Prognosis

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Cancers Metastatic to the Liver.
Rashidian N, Alseidi A, Kirks RC
Surg Clin North Am 2020 Jun;100(3):551-563. Epub 2020 Apr 3 doi: 10.1016/j.suc.2020.02.005. PMID: 32402300
Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P
Neuroendocrinology 2017;105(4):412-425. Epub 2017 Aug 12 doi: 10.1159/000475527. PMID: 28803232
Neuroendocrine Tumors.
Basuroy R, Srirajaskanthan R, Ramage JK
Gastroenterol Clin North Am 2016 Sep;45(3):487-507. doi: 10.1016/j.gtc.2016.04.007. PMID: 27546845
Carcinoid tumors.
Robertson RG, Geiger WJ, Davis NB
Am Fam Physician 2006 Aug 1;74(3):429-34. PMID: 16913162

Clinical prediction guides

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B
Science 2021 Feb 5;371(6529):602-609. Epub 2020 Dec 10 doi: 10.1126/science.abb5920. PMID: 33303685
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F
Ann Oncol 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108. PMID: 28368458
Autoimmune gastritis: Pathologist's viewpoint.
Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M
World J Gastroenterol 2015 Nov 14;21(42):12179-89. doi: 10.3748/wjg.v21.i42.12179. PMID: 26576102Free PMC Article
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A
J Clin Oncol 2012 Jul 20;30(21):2691-7. Epub 2012 May 21 doi: 10.1200/JCO.2012.41.6750. PMID: 22614989

Recent systematic reviews

Superficial versus total parotidectomy for metastatic cutaneous squamous cell carcinoma and melanoma of the head and neck: a systematic review.
Leong WS, Gowda S, Jackson R, Chabrillac E, Edafe O
J Laryngol Otol 2023 Jun;137(6):592-598. Epub 2022 Aug 1 doi: 10.1017/S0022215122001724. PMID: 35912693
Combined liver-intestinal and multivisceral transplantation for neuroendocrine tumors extending beyond the liver: A systematic literature review.
Duchateau NM, Canovai E, Vianna RM, Vanuytsel T, Verslype C, Mazariegos GV, Monbaliu D, Pirenne J, Ceulemans LJ
Transplant Rev (Orlando) 2022 Jan;36(1):100678. Epub 2022 Jan 21 doi: 10.1016/j.trre.2022.100678. PMID: 35090785
Metastasis to the rectum: A systematic review of the literature.
Janjic O, Labgaa I, Hübner M, Demartines N, Joliat GR
Eur J Surg Oncol 2022 Apr;48(4):822-833. Epub 2021 Oct 10 doi: 10.1016/j.ejso.2021.10.004. PMID: 34656391
Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis.
Almond LM, Hodson J, Ford SJ, Gourevitch D, Roberts KJ, Shah T, Isaac J, Desai A
Eur J Surg Oncol 2017 Oct;43(10):1808-1815. Epub 2017 May 25 doi: 10.1016/j.ejso.2017.05.016. PMID: 28583792
Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review.
Pezzilli R, Partelli S, Cannizzaro R, Pagano N, Crippa S, Pagnanelli M, Falconi M
Adv Med Sci 2016 Mar;61(1):147-53. Epub 2015 Oct 23 doi: 10.1016/j.advms.2015.10.001. PMID: 26774266

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...